But now, a device mainly used to treat migraines has just received emergency use authorization by the Food and Drug Administration to help COVID patients breathe a little easier.
"Antivirals, high-dose steroids, oxygen, inhalers, antibiotics, you name it," said Marshall Bedder, who was hospitalized with COVID-19.
Bedder was prescribed it all as doctors treated him for the coronavirus. He had difficulty breathing and his oxygen levels were low.
"When I was admitted, quite hypoxemic, in the seventies, I was worried," Bedder said.
Then this happened. His oxygen levels went from 91 to 95 in a few minutes and he could breathe easier. The reason behind the sudden relief? A device called GammaCore.
So, what is it?
"GammaCore Sapphire CV was recently authorized by the FDA for use in patients with COVID," said Peter Staats, MD. Staats is the chief medical officer at ElectroCore, which makes the device. He's also the chief medical officer of National Spine and Pain Centers, the largest integrated network of pain physicians in the United States.
The hand-held device works by sending electrical stimulation to the vagus nerve, which serves as the body's "command center" and plays a crucial role in relaying signals throughout the body.
After the vagus nerve is stimulated by the GammaCore, it can help open up the lungs, resulting in increased airflow in COVID-19 patients.
GammaCore, which is typically used to treat migraines, is now one of the latest tools in the fight against COVID-19.
"We may be able to alter the course of the disease such that, if you can breathe better, you won't need to go on a mechanical ventilator," Staats explained.
Patients can use this at home on their own, but they need a prescription from a doctor to obtain the device. Bedder got his device while he was in the hospital and he says it has made all the difference.
"Trust me, when you cannot breathe and there's no other options, it's a tremendous thing," Bedder said.
And there may be more benefits, other than the ones that can be seen immediately.
Staats says the stimulation that GammaCore provides to the vagus nerve can also reduce inflammation and possibly ease the long-term effects of COVID-19.
Report a correction or typo
RELATED TOPICS:
health & fitnesscircle of healthcoronaviruscovid 19 pandemic
Copyright © 2021 KABC-TV. All Rights Reserved.
Recent ECOR News
- electroCore Engages FNK IR to Execute Expanded Investor Relations Program • GlobeNewswire Inc. • 09/24/2024 12:00:00 PM
- Study Suggests Non-invasive Vagus Nerve Stimulation (nVNS) is effective in accelerating United States Air Force Pilot Training • GlobeNewswire Inc. • 09/10/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 09:05:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/06/2024 01:32:50 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/06/2024 01:32:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 12:46:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 01:37:31 PM
- electroCore to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 08/08/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:15:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:11:24 PM
- electroCore Announces Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/07/2024 08:01:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 08/02/2024 08:05:40 PM
- electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/02/2024 08:05:00 PM
- Non-invasive Vagus Nerve Stimulation (nVNS) is effective at accelerating foreign language learning • GlobeNewswire Inc. • 08/01/2024 12:00:00 PM
- electroCore to Announce Second Quarter June 30, 2024 Financial Results on Wednesday, August 7, 2024 • GlobeNewswire Inc. • 07/31/2024 12:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/23/2024 04:09:24 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/18/2024 07:40:06 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/17/2024 09:15:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 09:06:03 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/10/2024 08:07:23 PM
- electroCore Announces the Commercial Launch of TAC-STIM™ • GlobeNewswire Inc. • 06/25/2024 12:00:00 PM
- electroCore to Join Russell Microcap® Index • GlobeNewswire Inc. • 06/11/2024 12:00:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 06/07/2024 08:33:08 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM